[ad_1]
Experiments on the new type of coronavirus (Covid-19) vaccine candidate called “CoronaVac” developed by Sinavoc Biotech, a Chinese pharmaceutical company tested on humans in Brazil, were temporarily suspended.
TEMPORARILY STOPPED
According to the written statement of the Brazilian Health Regulatory Authority (Anvisa), a serious adverse event in human trials of CoronaVac in the country (a human drug for the purpose of preventing disease, diagnosing or treating a disease, or normalizing a physiological function, it was decided to temporarily suspend due to a harmful and unintended effect that occurred in the use of doses.
The statement indicated that the adverse event occurred on October 29, while no clear reason was given for the decision to suspend the trials.
An “adverse event” is defined as an unexpected side effect in the use of a drug. In the statement, it was reported that situations such as death, potentially fatal adverse event, disability or permanent disability, hospitalization of the patient were evaluated as “serious adverse events”.
THE HUMAN EXPERIMENTS BEGAN LAST JULY
CoronaVac’s experiments on humans in Brazil began in late July in collaboration with the Bhutantan Institute, which conducts biological research in Brazil.
In Brazil, which is among the countries most affected by the Covid-19 epidemic in the world, the virus, which has been seen in 5 million 675 thousand 32 people so far, caused the death of 162 thousand 628 people.
